Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

Brian I. Rini, David F. McDermott, Hans Hammers, William Bro, Ronald M. Bukowski, Bernard Faba, Jo Faba, Robert A. Figlin, Thomas Hutson, Eric Jonasch, Richard W Joseph, Bradley C. Leibovich, Thomas Olencki, Allan J. Pantuck, David I. Quinn, Virginia Seery, Martin H. Voss, Christopher G. Wood, Laura S. Wood, Michael B. Atkins

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha (IFN) and interleukin-2 (IL-2) have achieved complete responses, many of which have lasted for multiple decades. More recently, a large number of new agents have been approved for RCC, several of which attack tumor angiogenesis by inhibiting vascular endothelial growth factors (VEGF) and VEGF receptors (VEGFR), as well as tumor metabolism, inhibiting the mammalian target of rapamycin (mTOR). Additionally, a new class of immunotherapy agents, immune checkpoint inhibitors, is emerging and will play a significant role in the treatment of patients with RCC. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a Task Force, which met to consider the current role of approved immunotherapy agents in RCC, to provide guidance to practicing clinicians by developing consensus recommendations and to set the stage for future immunotherapeutic developments in RCC.

Original languageEnglish (US)
Article number81
JournalJournal for ImmunoTherapy of Cancer
Volume4
Issue number1
DOIs
StatePublished - Nov 15 2016

Fingerprint

Renal Cell Carcinoma
Immunotherapy
Neoplasms
Vascular Endothelial Growth Factors
Therapeutics
Vascular Endothelial Growth Factor Receptor
Advisory Committees
Sirolimus
Interferon-alpha
Interleukin-2

Keywords

  • Guidelines
  • Immunotherapy
  • Renal cell carcinoma
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Immunology and Allergy
  • Cancer Research
  • Molecular Medicine
  • Pharmacology
  • Immunology

Cite this

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. / Rini, Brian I.; McDermott, David F.; Hammers, Hans; Bro, William; Bukowski, Ronald M.; Faba, Bernard; Faba, Jo; Figlin, Robert A.; Hutson, Thomas; Jonasch, Eric; Joseph, Richard W; Leibovich, Bradley C.; Olencki, Thomas; Pantuck, Allan J.; Quinn, David I.; Seery, Virginia; Voss, Martin H.; Wood, Christopher G.; Wood, Laura S.; Atkins, Michael B.

In: Journal for ImmunoTherapy of Cancer, Vol. 4, No. 1, 81, 15.11.2016.

Research output: Contribution to journalArticle

Rini, BI, McDermott, DF, Hammers, H, Bro, W, Bukowski, RM, Faba, B, Faba, J, Figlin, RA, Hutson, T, Jonasch, E, Joseph, RW, Leibovich, BC, Olencki, T, Pantuck, AJ, Quinn, DI, Seery, V, Voss, MH, Wood, CG, Wood, LS & Atkins, MB 2016, 'Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma', Journal for ImmunoTherapy of Cancer, vol. 4, no. 1, 81. https://doi.org/10.1186/s40425-016-0180-7
Rini, Brian I. ; McDermott, David F. ; Hammers, Hans ; Bro, William ; Bukowski, Ronald M. ; Faba, Bernard ; Faba, Jo ; Figlin, Robert A. ; Hutson, Thomas ; Jonasch, Eric ; Joseph, Richard W ; Leibovich, Bradley C. ; Olencki, Thomas ; Pantuck, Allan J. ; Quinn, David I. ; Seery, Virginia ; Voss, Martin H. ; Wood, Christopher G. ; Wood, Laura S. ; Atkins, Michael B. / Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. In: Journal for ImmunoTherapy of Cancer. 2016 ; Vol. 4, No. 1.
@article{7e7fd0e5b8b849afabd5a5280ad7bded,
title = "Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma",
abstract = "Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha (IFN) and interleukin-2 (IL-2) have achieved complete responses, many of which have lasted for multiple decades. More recently, a large number of new agents have been approved for RCC, several of which attack tumor angiogenesis by inhibiting vascular endothelial growth factors (VEGF) and VEGF receptors (VEGFR), as well as tumor metabolism, inhibiting the mammalian target of rapamycin (mTOR). Additionally, a new class of immunotherapy agents, immune checkpoint inhibitors, is emerging and will play a significant role in the treatment of patients with RCC. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a Task Force, which met to consider the current role of approved immunotherapy agents in RCC, to provide guidance to practicing clinicians by developing consensus recommendations and to set the stage for future immunotherapeutic developments in RCC.",
keywords = "Guidelines, Immunotherapy, Renal cell carcinoma, Treatment",
author = "Rini, {Brian I.} and McDermott, {David F.} and Hans Hammers and William Bro and Bukowski, {Ronald M.} and Bernard Faba and Jo Faba and Figlin, {Robert A.} and Thomas Hutson and Eric Jonasch and Joseph, {Richard W} and Leibovich, {Bradley C.} and Thomas Olencki and Pantuck, {Allan J.} and Quinn, {David I.} and Virginia Seery and Voss, {Martin H.} and Wood, {Christopher G.} and Wood, {Laura S.} and Atkins, {Michael B.}",
year = "2016",
month = "11",
day = "15",
doi = "10.1186/s40425-016-0180-7",
language = "English (US)",
volume = "4",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

AU - Rini, Brian I.

AU - McDermott, David F.

AU - Hammers, Hans

AU - Bro, William

AU - Bukowski, Ronald M.

AU - Faba, Bernard

AU - Faba, Jo

AU - Figlin, Robert A.

AU - Hutson, Thomas

AU - Jonasch, Eric

AU - Joseph, Richard W

AU - Leibovich, Bradley C.

AU - Olencki, Thomas

AU - Pantuck, Allan J.

AU - Quinn, David I.

AU - Seery, Virginia

AU - Voss, Martin H.

AU - Wood, Christopher G.

AU - Wood, Laura S.

AU - Atkins, Michael B.

PY - 2016/11/15

Y1 - 2016/11/15

N2 - Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha (IFN) and interleukin-2 (IL-2) have achieved complete responses, many of which have lasted for multiple decades. More recently, a large number of new agents have been approved for RCC, several of which attack tumor angiogenesis by inhibiting vascular endothelial growth factors (VEGF) and VEGF receptors (VEGFR), as well as tumor metabolism, inhibiting the mammalian target of rapamycin (mTOR). Additionally, a new class of immunotherapy agents, immune checkpoint inhibitors, is emerging and will play a significant role in the treatment of patients with RCC. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a Task Force, which met to consider the current role of approved immunotherapy agents in RCC, to provide guidance to practicing clinicians by developing consensus recommendations and to set the stage for future immunotherapeutic developments in RCC.

AB - Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha (IFN) and interleukin-2 (IL-2) have achieved complete responses, many of which have lasted for multiple decades. More recently, a large number of new agents have been approved for RCC, several of which attack tumor angiogenesis by inhibiting vascular endothelial growth factors (VEGF) and VEGF receptors (VEGFR), as well as tumor metabolism, inhibiting the mammalian target of rapamycin (mTOR). Additionally, a new class of immunotherapy agents, immune checkpoint inhibitors, is emerging and will play a significant role in the treatment of patients with RCC. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a Task Force, which met to consider the current role of approved immunotherapy agents in RCC, to provide guidance to practicing clinicians by developing consensus recommendations and to set the stage for future immunotherapeutic developments in RCC.

KW - Guidelines

KW - Immunotherapy

KW - Renal cell carcinoma

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84998693391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998693391&partnerID=8YFLogxK

U2 - 10.1186/s40425-016-0180-7

DO - 10.1186/s40425-016-0180-7

M3 - Article

VL - 4

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

IS - 1

M1 - 81

ER -